PEGS Boston Virtual Summit
August 20, 2020
Presentation Title: Accelerating Therapeutic Antibody Discovery with Three Distinct Humanized Mouse Models Time: 9:45 AM – 10:10 AM EDT on Monday, August 31 Programs: Antibody for Cancer Therapy Speaker: Qingcong Lin, PhD, CEO, Biocytogen Boston Corp. With a robust immune response, RenMab™ Mouse produces fully-human antibodies with high specificity and diverse epitopes. To identify leads, […]
RenMab™ and RenLite™ Models Featured in GEN Magazine
August 19, 2020
RenMab™ Mouse Platform Drives SARS CoV-2 Neutralizing Antibody Cocktail Therapy Towards Clinical Trials in Biocytogen and Eucure Biopharma Partnership
August 13, 2020
[MA, USA and Beijing, China – August] The COVID-19 pandemic has been an inescapable, lethal, and overwhelming aspect of daily human life, threatening health and safety on a global scale. Biocytogen is excited to announce a breakthrough in scientific research and development (R&D) of therapeutic treatment strategy against the novel SARS CoV-2 viral spike protein […]
Webinar: Antibody Discovery Platforms and RenMab Mouse
June 29, 2020
This event has now passed. Now, you can view the Webinar on Youtube. Biocytogen Chief Scientific Officer and Head of Drug Discovery, Benny Yang PhD. will speak on the current landscape of antibody discovery platforms, with special focus on fully human antibody mice. Dr. Yang will explain the advantages and data-backed validation that come with using the RenMabTM Mouse for antibody discovery such as expedited screening of antibody […]
Webinar: Humanized Animal Models for Immunotherapy
June 29, 2020
This event has now passed. Now, you can view the Webinar on Youtube. Topic: Improve Translation of Humanized Animal Models for Immunotherapy Date: Thursday, July 16 2020, 11am-12pm EST. Webinar Description: Despite significant advances have been made in developing novel therapeutics for cancer treatment, only about five percent of new cancer drugs are approved, […]
Syngeneic Mouse Models and Humanized Immune-Checkpoint Mice
June 17, 2020
Why do we need Syngeneic Mouse Models? To test potential immuno-oncology therapeutics in vivo, it is necessary to ensure that the disease model used has an intact immune system. Immunotherapeutics work with the body’s immune system to fight cancer cells. Often through inhibiting specific cell receptors called immune checkpoints, immunotherapeutics seek to bind to receptors […]
Online: Tumor Models Boston Summit 2020
June 17, 2020
In Vivo Efficacy & Toxicity Evaluation Using Various Humanized Mouse Models to Increase Clinical Translation Time: Saturday, July 15 2020. 9:30 AM EST. Speaker: Qingcong Lin, CEO of Biocytogen Boston Corp Discuss and evaluate IO target humanized mouse models, including hCD3e models for IO antibody efficacy evaluation How can Cytokine/Cytokine receptor humanized mouse models be used […]
AACR Virtual Annual Meeting II (Poster Session)
June 3, 2020
The AACR Foundation is the philanthropic arm of the American Association for Cancer Research (AACR). The Foundation supports the groundbreaking work of the AACR and its more than 47,000 members on the front lines of the global effort to eradicate cancer. The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer […]
Biocytogen is Featured in GEN’s Immunotherapy and Cancer Supplement Issue
April 10, 2020
Developing animal models for immunotherapy is often difficult due to the complexity of the immune system and tumor biology. Showcased in April’s GEN Magazine, Biocytogen presents a line of target-humanized mice models, covering a growing portfolio of immune checkpoints and cytokines alongside its flagship RenMab fully human antibody mouse. Biocytogen has also developed the immunodeficient […]
Biocytogen CEO’s Response During COVID-19 Pandemic
April 8, 2020
Dear Valued Customer, The COVID-19 global outbreak has undoubtedly brought upon difficult times for individuals, families, and businesses around the world. Many of us have never experienced an interruption of life at this scale. Amid this turmoil, I wanted to provide some status updates. Today, I am very glad to let you know that all […]
